The European Investment Bank's financing will enable Cape Biologix Technologies Ltd. to build a new production unit, develop its processing laboratories and build air-conditioned hydroponic chambers in Mauritius. These new facilities will enable the company to produce the plant protein used as reagent in quick detection kits for Covid-19 and endemic diseases in Africa (in particular HIV, Ebola, dengue and yellow fever).
The project, worth EUR 47.5 million, will receive the financial backing of the EIB in an amount of EUR 33.3 million.
Gide advised the EIB with a team comprising counsel Farah El Bsat, and associate Eric Bolis.
Allen & Overy advised Cape Biologix Technologies and its shareholders, with a team comprising partner Driss Bererhi in Paris and associate Pravesh Lallah in Johannesburg.
The Mauritius counsel to the EIB was firm Legis and Partners Ltd, with a team comprising Robert Ferrat, Caroline Samy and Sahirun Subadar Agathee.
The Mauritius counsel to the borrower was firm BLC Robert & Associates, with a team comprising Valérie Bisasur and Leticia Esther.